Venetoclax, an inhibitor of the BCL2 family, has been approved for patients with chronic lymphocytic and acute myeloid leukemias45,46 and has been reported to be clinically active in patients with R/R T-ALL combined with salvage therapy47–51. Here, BCL2 is linked to acute lymphoblastic leukemia.